Enveda Biosciences has raised $430M across 2 funding rounds, plus 1 undated round. The company is valued at $650M (post-money).
Enveda Biosciences raised $55 million in new funding to accelerate its AI drug-discovery platform and advance several candidates into clinical trials. The round supported the company's platform, which searches its database of natural compounds by chemical structure, biological activity and organ distribution to identify promising drug candidates quickly.
2 funding rounds, the latest highlighted.
Enveda Biosciences was founded in 2018, United States.
No date is disclosed for this round.
A primary round — the company sells new shares to investors it selects. $130M raised, led by Kinnevik.
No filing has been made.
2 dated rounds, newest first.
Premji InvestLEADKKinnevikLEADFFPV
MicrosoftDDimension
Lux CapitalThe last valuation is $650M.
Lead investors for each round are in the funding timeline.
The closest ai drug discovery peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
No. Enveda Biosciences is a private company; its shares do not trade on a public exchange.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
